Streptococcus pyogenes Su strain cells 1KE (0.1mg) powder and solvent for suspension for injection vials
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Streptococcus pyogenes Su strain cells on the MHRA register
Picibanil 1KE (0.1mg) powder and solvent for suspension for injection vials
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0.
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 7 · 1984–2026
Showing the 50 most relevant studies, sorted by most relevant.
Magdalena Rzewuska, Ewelina Kwiecień, Dorota Chrobak‐Chmiel, et al.
International Journal of Molecular Sciences, 2019
- Actinomycetaceae
- Bacterial Toxins
- Disease Reservoirs
Mohammad A, Yurina A, Simonyan T, et al.
2024
- Neoplasms
- Immunotherapy, Adoptive
- Receptors, Chimeric Antigen
BackgroundModular (universal) CAR T-platforms were developed to combat the limitations of traditional CAR-T therapy, allowing for multiple targeting of tumor-associated antigens and the ability to control CAR-T cell activity. The modular CAR-T platform consists of a universal receptor (signaling module) that recognizes an adapter molecule on the soluble module, which is responsible for antigen recognition. Multiple platforms have been developed over the last 12 years, and some of them have entered the clinical trial phase. This systematic review seeks to evaluate the different parameters of modular CAR-T platforms performance in animal models.MethodsA systematic search of literature in the PubMed database and in Google Scholar and BASE (Bielefeld Academic Search Engine) search engines was performed according to predefined eligibility criteria. All studies conducted on xenograft mouse models with any variant of modular CAR-T platforms were included. Forest plots were generated for visual presentation of the extracted quantitative findings (standardized mean difference (SMD) and median survival rate (MSR)).ResultsA total of 33 studies employing 15 different modular CAR-T platforms were included. The platforms varied in terms of CAR-T cells, soluble module doses, and their frequency of administration. The studies showed a reduction in tumor burden and in tumor volume compared to the combined negative group. In comparison with the positive control group, there was no significant change in tumor burden or volume. In all the included studies the experimental group had a higher survival probability compared to the combined negative group at the study endpoint, with no significant difference in survival rate compared to the positive control group.ConclusionThe modular CAR-T platforms are generally effective and are a valuable addition to the arsenal of CAR therapy.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/ PROSPERO, identifier CRD42023443984.
Abstract licence: CC BY
Marco Terreni, Marina Taccani, Massimo Pregnolato
Molecules, 2021
- Meropenem
- Cefiderocol
- Anti-Bacterial Agents
Amin Mahmood Thawabteh, Salma Juma, Mariam Bader, et al.
Toxins, 2019
- Herbivory
- Alkaloids
- Anti-Infective Agents
Iliya Dauda Kwoji, Olayinka Ayobami Aiyegoro, Moses Okpeku, et al.
Biology, 2021
Asmat Ullah Khan, Rongmei Qu, Tingyu Fan, et al.
Stem Cell Research & Therapy, 2020
- Osteogenesis
- Mesenchymal Stem Cells
- Actins
Lucas Miranda Fonseca, Lucas S. Parreiras, M.T. Murakami
Biotechnology for Biofuels, 2020
J. Sutcliffe, A. Tait-Kamradt, L. Wondrack
Antimicrobial Agents and Chemotherapy, 1996
Bang Shen, Kevin M. Brown, Tobie D. Lee, et al.
mBio, 2014
- Clustered Regularly Interspaced Short Palindromic Repeats
- Base Sequence
- Tetrahydrofolate Dehydrogenase
Minja Miettinen, Sampsa Matikainen, Jaana Vuopio‐Varkila, et al.
Infection and Immunity, 1998
- Gram-Positive Bacteria
- Interferon-gamma
- Lactobacillus
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Scientific data (pharmacology, interactions, ADME) is not yet available for this medicine. Clinical sections are sourced from the NHS dm+d database.